Previous study demonstrated that DLBCL has pro-tumor mechanisms by expressing IL-6/IL-6R and inhibiting negative regulator, eventually promoting the constitutive activation of IL-6/IL-6R axis [33]. The gene discussed is IL6R; the disease is diffuse large B-cell lymphoma.